About: Delivering the power of nanomedicine to patients today

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Delivering the power of nanomedicine to patients today Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Delivering the power of nanomedicine to patients today
Creator	Tosi, Giovanni Metcalfe, Su Schiffelers, Raymond Caputo, Fanny Ceccaldi, Alexandre Germain, Matthieu Pottier, Agnes Schmid, Ruth Spring, Kathleen
Source	Elsevier; Medline; PMC
abstract	The situation of the COVID-19 pandemic reminds us that we permanently need high-value flexible solutions to urgent clinical needs including simplified diagnostic technologies suitable for use in the field and for delivering targeted therapeutics. From our perspective nanotechnology is revealed as a vital resource for this, as a generic platform of technical solutions to tackle complex medical challenges. It is towards this perspective and focusing on nanomedicine that we take issue with Prof Park's recent editorial published in the Journal of Controlled Release. Prof. Park argued that in the last 15 years nanomedicine failed to deliver the promised innovative clinical solutions to the patients (Park, K. The beginning of the end of the nanomedicine hype. Journal of Controlled Release, 2019; 305, 221–222 [1]. We, the ETPN (European Technology Platform on Nanomedicine) [2], respectfully disagree. In fact, the more than 50 formulations currently in the market, and the recent approval of 3 key nanomedicine products (e. g. Onpattro, Hensify and Vyxeos), have demonstrated that the nanomedicine field is concretely able to design products that overcome critical barriers in conventional medicine in a unique manner, but also to deliver within the cells new drug-free therapeutic effects by using pure physical modes of action, and therefore make a difference in patients lives. Furthermore, the >400 nanomedicine formulations currently in clinical trials are expecting to bring novel clinical solutions (e.g. platforms for nucleic acid delivery), alone or in combination with other key enabling technologies to the market, including biotechnologies, microfluidics, advanced materials, biomaterials, smart systems, photonics, robotics, textiles, Big Data and ICT (information & communication technologies) more generally. However, we agree with Prof. Park that “ it is time to examine the sources of difficulty in clinical translation of nanomedicine and move forward “. But for reaching this goal, the investments to support clinical translation of promising nanomedicine formulations should increase, not decrease. As recently encouraged by EMA in its roadmap to 2025, we should create more unity through a common knowledge hub linking academia, industry, healthcare providers and hopefully policy makers to reduce the current fragmentation of the standardization and regulatory body landscape. We should also promote a strategy of cross-technology innovation, support nanomedicine development as a high value and low-cost solution to answer unmet medical needs and help the most promising innovative projects of the field to get better and faster to the clinic. This global vision is the one that the ETPN chose to encourage for the last fifteen years. All actions should be taken with a clear clinical view in mind, “ without any fanfare”, to focus “on what matters in real life”, which is the patient and his/her quality of life. This ETPN overview of achievements in nanomedicine serves to reinforce our drive towards further expanding and growing the maturity of nanomedicine for global healthcare, accelerating the pace of transformation of its great potential into tangible medical breakthroughs.
has issue date	2020-10-10(xsd:dateTime)
bibo:doi	10.1016/j.jconrel.2020.07.007
bibo:pmid	32681950
has license	no-cc
sha1sum (hex)	5370a4ae6200b9ee76fb8dbede9c46e4053025f4
schema:url	https://doi.org/10.1016/j.jconrel.2020.07.007
resource representing a document's title	Delivering the power of nanomedicine to patients today
has PubMed Central identifier	PMC7362824
has PubMed identifier	32681950
schema:publication	J Control Release
resource representing a document's body	covid:5370a4ae6200b9ee76fb8dbede9c46e4053025f4#body_text
is schema:about of	named entity 'pandemic' named entity 'promised' named entity 'COVID-19' named entity 'European Technology Platform' named entity 'nanomedicine' named entity 'failed' named entity 'technical' named entity 'Release' named entity 'technologies' named entity 'Journal of Controlled Release' named entity 'nanomedicine' named entity 'nanomedicine' named entity 'Prof.' named entity 'x-ray' named entity 'nanotechnology' named entity 'Nanomedicine' named entity 'quality of life' named entity 'NIST' named entity 'drug product' named entity 'doxorubicin' named entity 'therapeutic antibodies' named entity 'nanomedicine' named entity 'cornea' named entity 'Nanomedicine' named entity 'immunological effects' named entity 'National Institute' named entity 'COVID-19' named entity 'colloids' named entity 'synergic' named entity 'liposome' named entity 'nucleic acid' named entity 'R&D' named entity 'nanomedicine' named entity 'genetic disorder' named entity 'nanomedicine' named entity 'nanomedicine' named entity 'H2020' named entity 'vaccine' named entity 'Nanomedicine' named entity 'Nanoscale' named entity 'hyperthermia' named entity 'nanocrystal' named entity 'CNS' named entity 'SMEs' named entity 'nucleic acids' named entity 'hyperthermia' named entity 'dendrimer' named entity 'medicinal products' named entity 'endotoxins' named entity 'clinical trials' named entity 'Abraxane' named entity 'R&D' named entity 'mRNA' named entity 'vaccines' named entity 'Horizon Europe' named entity 'protein' named entity 'nanomedicine' named entity 'big pharma' named entity 'metrology' named entity 'Horizon Europe' named entity 'drug delivery' named entity 'SMEs' named entity 'axiomatic design' named entity 'clinical trials' named entity 'NBTXR3' named entity 'therapeutic window' named entity 'nanomedicines' named entity 'Europe' named entity 'GMP' named entity 'Ebola' named entity 'AMD' named entity 'precision engineering' named entity 'cancer vaccines'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software